首页 | 本学科首页   官方微博 | 高级检索  
     


Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies
Authors:Daisuke Minakata  Shin-ichiro Fujiwara  Daizo Yokoyama  Atsuto Noguchi  Shuka Aoe  Takashi Oyama  Shunsuke Koyama  Rui Murahashi  Hirotomo Nakashima  Kazuki Hyodo  Takashi Ikeda  Shin-ichiro Kawaguchi  Yumiko Toda  Shoko Ito  Takashi Nagayama  Kiyomi Mashima  Kento Umino  Kaoru Morita  Masahiro Ashizawa  Chihiro Yamamoto  Kaoru Hatano  Kazuya Sato  Ken Ohmine  Yoshinobu Kanda
Affiliation:Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan
Abstract:
The prognosis of multiple myeloma (MM) has dramatically improved with the development of new drugs, and it has become important to determine the appropriate combinations of these novel agents. This study was a systematic review and network meta-analysis (NMA) of randomized trials in patients with relapsed and/or refractory (RR) MM. The PubMed, Cochrane, and Embase databases were searched for randomized trials from 1 January 2002 to 28 February 2022 of patients treated for MM. The primary end-point was progression-free survival (PFS), evaluated as a hazard ratio (HR) with a 95% confidence interval (95% CI) compared to dexamethasone (DEX). The p-score was used to rank treatments. Of a total of 1136 abstracts screened, 37 studies were selected, including 34 treatment options for RRMM. Daratumumab, lenalidomide and DEX was found to be the best treatment for RRMM, with the best HR compared to DEX (HR, 0.13; 95% CI, 0.08–0.20; p-score 0.9796). There was no evidence of significant heterogeneity (I2, 41.3%; p = 0.146). The current NMA confirmed the excellent efficacy of three-drug regimens including anti-CD38 antibodies to treat RRMM and provides background data to evaluate the efficacy of chimeric antigen receptor T-cell treatments and bispecific T-cell engager therapies.
Keywords:double-refractory myeloma  high risk myeloma  network meta-analysis  plasma cell malignancy
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号